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ABSTRACT  
Background  
Research suggests that sleep disturbance is common in psoriasis. Despite 32 studies 
conducted in sleep, many demonstrate methodological flaws, often using unvalidated 
measurement, with no study examining multiple dimensions of sleep-wake functioning. 
Moreover, research has yet to comprehensively examine the range of physical and 
psychological factors that may affect sleep in people with psoriasis. 
Objective  
To characterise sleep disturbance using validated measures and identify physical and 
psychological predictors of sleep quality in people with psoriasis. 
Methods   
An online survey was conducted (n=186;Mage=39.2) comprising validated measures 
assessing sleep (Pittsburgh Sleep Quality Index [PSQI], Berlin Questionnaire, Pre-Sleep 
Arousal Scale), chronotype (Morningness-Eveningness Questionnaire), mood (Hospital 
Anxiety and Depression Scale), itch (5-D Itch Scale) and psoriasis severity (Simplified 
Psoriasis Index). Group comparisons and regression analyses were used to examine 
predictors of poor sleep. 
Results    
Mean PSQI score was 9.24 (SD=4.32), with 76.3% scoring above the threshold for poor 
sleep (≥ 6 on the PSQI) and 32.5% scoring ‘positive’ for probable obstructive sleep apnoea. 
Poor sleep and high likelihood of OSA was associated with more severe psoriasis (p<.05; 
What is already known about this topic? 
• Estimated rates of sleep disturbance in psoriasis vary widely  
• Current research does not provide a comprehensive assessment of sleep, 
including possible physical and psychological factors associated with poor sleep. 
What does this study add? 
• Poor sleep is common, affecting over 75% of our sample. 
• Poor sleep quality is associated with pre-sleep cognitive arousal, itch, low mood 
and pre-sleep somatic arousal.  
• Possible treatment targets for improved sleep are identified. 
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η2=.07; η2=.005). Cognitive arousal (β=.264, p=.001), itch (β=.260, p<.001) and depression 
(β=.236, p=.001) were the most robust predictors of poor sleep quality which, together with 
somatic arousal (β=.168, p=.022), accounted for 43% of variance in PSQI scores. 
Conclusions   
Poor sleep is common in psoriasis and associated with psychological and physical factors. 
Rates of probable obstructive sleep apnoea are also high. Given the importance of 
restorative sleep for health, sleep complaints should receive greater clinical attention in the 
management of psoriasis.  
 
INTRODUCTION 
Psoriasis is a complex immune-mediated inflammatory disease primarily impacting on skin 
and affecting 2-3% of the population worldwide1. It has well established associations with a 
number of other conditions, including: cardiovascular disease (CVD)2, inflammatory bowel 
disease3, psoriatic arthritis4, diabetes5, and depression and anxiety6. The disease burden of 
psoriasis is greater than other chronic dermatological conditions7 and equivalent to that 
experienced in cancer, CVD and arthritis populations8.  
There is mounting interest in the relationship between sleep and psoriasis. A systematic 
review by our group showed that a high proportion (ranging from 0.05% to 87.5%) of 
individuals with psoriasis may experience sleep disturbances9, which are associated with 
itch, psychological distress (low mood and anxiety), pain and obstructive sleep apnoea 
(OSA)9. However the published literature demonstrates substantial variation in rates of 
disturbed sleep, and is limited by poor measurement of sleep, with many studies using 
unvalidated measures, in some cases just a single question. Indeed, lack of a 
comprehensive and valid examination of sleep, alongside incomplete data reporting9 10, has 
hindered our understanding of sleep in psoriasis.  
Sleep disturbance, including OSA, is associated with a range of adverse health outcomes 
including elevated risk for a range of physical diseases, several of which people with 
psoriasis are already more susceptible to (e.g. diabetes11, hypertension12, CVD13). Moreover, 
sleep disturbance increases risk of psychological illness (e.g. depression14, anxiety15) and, 
over time, all-cause mortality16. Sleep is essential for metabolic17 and immunological 
health18, while sleep disturbance may be pro-inflammatory and impact on psoriasis activity18-
20
. Indirect evidence supporting the impact of sleep on inflammation in psoriasis comes from 
a recent epidemiological study showing that the presence of a comorbid sleep disorder 
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increases CVD risk by 25% in psoriasis patients21. Additionally, relationships between 
circadian factors and psoriasis have been identified, with a longitudinal study reporting that 
regular night-shift work is associated with increased risk of developing psoriasis22. Circadian 
misalignment may disrupt normative metabolic and endocrine functioning, leading to adverse 
cardiometabolic complications, possibly through impairment of normal melatonin functioning. 
Melatonin, is involved in both sleep 23, and regulates inflammatory responses24, and may 
lead to increased risk of psoriasis onset if chronically disrupted22.  
Based upon the strong links identified between sleep, health and psoriasis, a 
multidimensional assessment of sleep in this population is warranted. Whilst previous 
studies provide evidence of sleep disturbance in psoriasis, few studies have measured 
multiple domains of sleep disturbance in psoriasis patients using validated tools9. A range of 
validated measures must be used to comprehensively assess the range of sleep 
dimensions, including sleep timing (i.e. chronotype), sleep quality, sleep continuity and sleep 
duration. Due to the limited appraisal of potential predictors of sleep quality in psoriasis we 
sought to examine the role of thesein predicting poor sleep focusing on variables associated 
with poor sleep in psoriasis including low mood14 15 25 26, anxiety15 27 28 and itch29 30 and more 
generally, pre-sleep arousal31-33.  Our aims were as follows: firstly to examine multiple 
dimensions of sleep-wake functioning in a representative community-based sample, and 
secondly, to identify the predictors of sleep disturbance, focusing on both physical and 
psychological variables known to interact with sleep in psoriasis.  
 
METHODS 
Design 
We conducted a cross-sectional online survey using SelectSurvey.NET (v4.146.001, 
ClassApps, Overland Park, KS, USA). This allowed an international sample to access the 
survey, and enabled participants to complete it in their own time. 
Recruitment 
Links for the survey were distributed via social media sites by the Psoriasis Association of 
Great Britain and Ireland, the National Psoriasis Foundation, the Canadian Psoriasis 
Association, The British Skin Foundation, and were posted on Facebook groups for 
members of the New Zealand Psoriasis Association along with other psoriasis support 
groups. Additional snowballing techniques were used: the survey link was distributed by the 
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IMPACT research group’s (www.impactpsoriasis.org.uk) professional contacts, an existing 
psoriasis research database and through posters placed in a UK University.  
Participants 
Inclusion criteria included (i) a diagnosis of plaque psoriasis from a healthcare professional, 
(ii) ≥18 years old and (iii) a good understanding of English. The survey was available to any 
individual with psoriasis regardless of whether or not they were experiencing sleep 
disturbance to ensure that variation in sleep quality was captured.  
Procedure and analysis 
Upon opening the survey link, participants were presented with an information sheet 
explaining the study’s aims, content and research team contact details. Consent was 
provided online immediately preceding participation. Demographic questions, measures 
relating to sleep, mood, psoriasis, and itch were presented for completion and included: 
Pittsburgh Sleep Quality Index (PSQI)34 35 - Assesses sleep quality and disturbance over one 
month. It consists of 19 items scored across 7 components which yield a global score 
ranging from 0 to 21. A score of ≤5 indicates normal sleep whereas ≥6 indicates poor sleep.  
Berlin Questionnaire36 – A screening questionnaire used to assess risk for the development 
of OSA.  It consists of 3 categories containing a total of 10 items. Positive scores in >2 
categories indicate high OSA risk and low risk if <1 category is positive.  
Morningness-Eveningness Questionnaire (MEQ)37 – Ascertains when an individual’s peak 
alertness is (morning, evening or in between) over 19 multiple choice questions. Scores 
correspond to the following chronotypes: 16-30 – definite evening, 31-41 – moderate 
evening, 42-58 – intermediate, 59-69 – moderate morning, and 70-86 – definite morning. 
Pre-Sleep Arousal Scale (PSAS)38 39 - Quantifies cognitive and somatic arousal during the 
pre-sleep period. It consists of 16 items across 2 subscales, one assessing cognitive arousal 
and the other somatic arousal with scores ranging from 8 to 40. A higher score indexes 
greater pre-sleep arousal. 
Hospital Anxiety and Depression Scale (HADS)40 41 – An established measure of depression 
and anxiety comprising 14 items, with 7 relating to depression and 7 relating to anxiety (each 
subscale scored between 0 and 21). A higher score reflects greater distress. A cut-off score 
of 9 for each subscale indicates ‘caseness’ for probable clinical levels of ditress41. 
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Simplified Psoriasis Index-Severity Score (SPI-S)42 – A self-assessment of psoriasis severity 
asking participants to rate the extent and plaque thickness which are multiplied to obtain a 
severity score. Scores range from 0-50 with a higher score indicating more severe psoriasis. 
An SPI-S score of <5, <10, >18, >19 and >20  is equivalent to a Psoriasis Area Severity 
Index score of <5,<10, >15 , >18 and >20 respectively43.  
5-D Itch Scale44 - A measure of the degree, duration, direction, disability and distribution of 
itch. It can be calculated to provide a global score of itch severity and impact. Scores can 
range from 5 (no itch) to 25 (severe itch). 
All questions on each page had to be completed in order to progress to the next page. 
Ethical approval for this study was obtained in June 2015 (ref: 15/LO/1052). 
Statistical analyses 
Descriptive data were obtained for all variables. Normality was assessed and due to 
positively skewed data, bootstrapping based upon 5000 replications was applied to tests 
using psoriasis severity.  Associations between questionnaire variables were tested using 
Pearson’s product moment correlations and point-biserial correlations when using OSA 
probability. Independent t-tests were used to compare psoriasis severity scores for normal 
(PSQI≤5) and poor sleepers (PSQI≥6) and to compare psoriasis severity scores between 
those with a high and low likelihood for OSA. A one-way analysis of variance (ANOVA) 
compared psoriasis severity scores for morning, intermediate and evening chronotype 
groups. Relative between-group effect sizes, expressed as eta-squared (η2), were applied to 
estimate and compare the magnitude of observed effects. To examine which factors 
predicted poor sleep a multiple linear regression was performed for all variables that 
correlated with sleep (r≥.4)45 entered simultaneously. All analyses were conducted on SPSS 
(v22.0, IBM Corporation; Armonk, NY, USA).  
 
RESULTS 
Sample characteristics 
One hundred and eighty-six people (140 [75.3%] female; Mage = 39 years; range 18-70 
years) from 15 countries (UK, USA, Canada, New Zealand, Australia, Ireland, Germany, 
Greece, Argentina, Egypt, India, France, Italy, Denmark, Puerto Rico) completed the survey 
between June 2015 and January 2016, providing complete data. Partial data was obtained 
from 241 participants, however, many dropped out in the initial pages of the survey. Rather 
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than substitute data for partially complete responses we chose to use complete data only. 
Psoriasis severity was predominantly mild with a sample mean SPI-S score of 9.56 
(SD=8.58). Mean score for the depression and anxiety subscales were  below the clinical 
threshold at 6.52 (SD=4.24) and 8.56 (SD=4.34) respectively41.   
Sleep Characteristics 
Of 186 participants, 76.3% (n=142) were classified as poor sleepers with the sample having 
a mean PSQI score of 9.24, SD=4.32. Sixty-one (32.6%) participants had a high probability 
of OSA as determined by the BQ. Consistent with elevated OSA probability, the mean BMI 
for the sample was high at 30.7 kg/m2, with 26.4% overweight (>25kg/m2) and 44.8% obese 
(>30 kg/m2). Regarding pre-sleep arousal, the mean score for the cognitive subscale was 
21.01 (SD=7.5) and 14.53 (SD=5.85) for the somatic subscale. The mean MEQ score for the 
sample was 51.43 (SD=9.98), with the majority possessing an intermediate chronotype 
(62.9%), followed by morning (23.1%) then evening (14%). 
Participants’ mean total sleep time was 371.3 (SD=89.14) minutes with 83.3% classified as 
short sleepers (<7 hours), 14.5% as normal sleepers (7-9 hours) and 2.2% as long sleepers 
(>9 hours)46. Mean sleep efficiency for the sample was relatively poor at 75.34% 
(SD=17.33), with a mean sleep onset latency of 42.37 (SD=44.04) minutes. Reported sleep 
problems related to poor subjective sleep quality (51%) two or more times per week, 
difficulties initiating sleep (52.1%) two or more times per week and difficulty with both 
maintaining sleep along with early awakening from sleep (79%) two or more times per week. 
Participants’ also reported difficulties sleeping due to being too hot and experiencing pain. 
Further detail on these can be seen in S1.  
Descriptive data for all variables are presented in Table 1. Comparisons of mean scores for 
normal and poor sleepers for each continuous measure can be seen in Figure 1.  
 
A significant difference was present in psoriasis severity scores between normal sleepers 
(M=6.36; SD=5.44) and poor sleepers (M=10.55; SD=9.14 t(184)=3.73, p<.001,η2=.07), with 
poor sleepers having significantly higher psoriasis severity scores. Similarly, individuals with 
a high probability of OSA (M=11.58, SD=10.30) had significantly higher psoriasis severity 
scores than those with a low probability (M=8.58, SD=7.45 t(184) = 2.03, p<.05,η2=.005). 
There were no significant differences in psoriasis severity scores between morning (M=7.75, 
SD=6.86), intermediate (M=10.19, SD=8.69), and evening (M=9.69, SD=10.39) chronotype 
groups, (p=.281; η2=.014). 
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Predictors of sleep quality 
Next, we evaluated the contribution of variables (age, sex, BMI, psoriasis severity, mood, 
itch, pre-sleep arousal, chronotype and OSA risk) to variation in sleep quality. Sleep quality 
was significantly positively correlated with psoriasis severity, anxiety, depression, itch, 
somatic arousal and cognitive arousal and negatively correlated with chronotype (Table 2). 
All variables except psoriasis severity, chronotype and OSA probability correlated with sleep 
quality at r≥.4. Therefore, anxiety, depression, itch, and somatic and cognitive arousal were 
included in the subsequent regression analysis (Table 3).  
 
Multiple regression analysis indicated that cognitive arousal (β=.264, p<.05), itch (β=.260, 
p<.0001), depression (β=.236, p<.05) and somatic arousal (β=.168, p<.05) were 
independent predictors of sleep quality, together accounting for 43% of variance in PSQI 
scores. 
 
DISCUSSION 
The aim of this study was to characterise sleep in psoriasis and to examine the predictors of 
sleep quality. Our results show that poor sleep quality may be more common in psoriasis 
(76.3%) than estimates in the general population (30-50%)47. Indeed, sleep quality and sleep 
efficiency were worse than previously reported in psoriasis 48-50 or diabetes samples51 and 
equivalent to that shown in a psoriatic arthritis sample52. Additionally, we observed a high 
probability of OSA in our sample (32.5%), again at a rate higher than the prevalence in the 
general population (3-7%)53, although somewhat lower than the rate of around 50% reported 
in other psoriasis samples54 55. 
Short sleep duration (<7 hours) was common in our sample, reported by the majority 
(83.3%). Short sleep duration has well established links with negative health consequences 
including obesity56, diabetes57 58 and hypertension59 and thus may contribute to increased 
disease burden. Participants reported difficulties initiating and maintaining sleep, alongside 
early awakening with an inability to resume sleep; these are core features of insomnia60. 
Indeed, there was high pre-sleep cognitive and somatic arousal in our sample, at least as 
high as clinical insomnia patients61. Pre-sleep arousal is a known feature of insomnia, 
frequently precipitating and contributing to sleep difficulties31 62manifesting as cognitive 
(rumination, worry and negative emotion)32, somatic (elevated sympathetic activity, 
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metabolic rate and hypothalamic-pituitary-adrenal axis activity)63-65 and cortical (increased 
brain metabolism and high-frequency EEG activity)66 67 hyper-arousal.  
The elevated OSA probability present in our sample is consistent with the high mean BMI 
score found, with obesity a known risk factor for OSA68 and common in people with 
psoriasis69. It is likely that lifestyle factors (e.g. obesity, physical inactivity) are involved and 
may contribute to this elevated risk55. Nevertheless, it has been proposed that psoriasis and 
OSA are linked bi-directionally via inflammatory pathways, with both disorders demonstrating 
increased concentrations of interleukin (IL)-17, IL-6 and tumour necrosis factor (TNF)-α70-73. 
Whilst the precise mechanisms linking OSA and psoriasis remain unclear, there is some 
evidence suggesting links between lifestyle factors and CVD/hypertensionmay underlie this 
elevated risk74. It is worth mentioning that OSA estimates in this study are lower than 
reported elsewhere9 and may be due to the use of a self-report measure (Berlin 
Questionnaire) rather than polysomnography to assess OSA. However, the Berlin 
Questionnaire has proven validity, and a moderate-strong positive predictive value, ranging 
from .7275 to .8936. Given that OSA is a known risk factor for CVD76, ischemic stroke77, road 
traffic accidents78 and hypertension79 we suggest that sleep disordered breathing is queried 
in patients with psoriasis to facilitate appropriate diagnosis and treatment. 
Cognitive arousal, itch, depression and somatic arousal were identified as key predictors of 
sleep quality. Elevated arousal in the pre-sleep period is associated with sleep difficulties in 
insomnia and healthy individuals, contributing to increased sleep onset latency, reduced 
sleep efficiency and total sleep time and sleep-state misperception31-33. Although 
speculative, a number of factors may contribute to elevated arousal in psoriasis including 
disease-related rumination and worry, and monitoring of somatic symptoms, such as itch. 
Further arousal may stem from disrupted emotional regulation, resulting in negatively-toned 
emotional activity with sleep disturbances known to modulate emotional responses80 81. It is 
likely that anxiety did not emerge as a significant predictor due to the probable shared 
variance between the HADS-A and PSAS-C subscales. The content of this elevated arousal 
in the pre-sleep period could be investigated further, examining psoriasis-specific factors. 
Itch and associated scratching have been reported as disrupting sleep in psoriasis and other 
pruritic conditions, with scratching occurring throughout the sleep period82-85. Evidence 
suggests conditioned scratching activity can occur during sleep, with nocturnal scratching 
reported as a distinct parasomnia in a number of cases86.  Moreover, itch has strong links 
with mood87, with depression amplifying itch perception88. In addition, well-established links 
between depression and sleep exist, with low mood and insomnia interacting bidirectionally14 
89
 suggesting the existence of shared aetiology14 26. Future research could focus on 
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prospectively examining the causal direction between these predictors and poor sleep with 
the aim of identifying possible mediating pathways.  
A key strength of this study is that it provides a multidimensional assessment of sleep using 
validated measures in an international sample. Despite this, there are limitations that must 
be considered.  First, our study may have been subject to selection bias with people that 
experience sleep disruption having a greater motivation to participate. We attempted to 
minimise this by inviting all individuals with psoriasis regardless of sleep status to participate. 
Moreover, although the majority of our sample had mild psoriasis, magnitude of sleep 
disturbance and high levels of pre-sleep arousal suggest that poor sleep is a prevalent issue 
in this group. We believe the distribution of psoriasis severity observed in this study is 
sufficiently similar to that found elsewhere90. It is unclear, however, why there was a 
predominance of women participating in the study. It could be speculated that this is due to a 
higher prevalence of insomnia, thus may be the result of selection bias91. Indeed, evidence 
suggests women are more likely to respond to survey research with similar gender 
distributions to those encountered here observed in other sleep-related survey studies92 93. It 
is also unclear why we obtained a low participation rate relative to the recruitment efforts. 
Over 11,800 individuals engaged with the survey link, however 11,471 did not continue past 
the information sheet. We are unsure why this is, however, a contributing factor may have 
been the number of questions included. Another significant limitation of this study is the lack 
of a control group, limiting our ability to generalise the prevalence of sleep disturbance found 
in this study to the psoriasis population as a whole. A further limitation stems from the use of 
subjective sleep measures, which, whilst valid, were retrospective in nature and thus may be 
subject to recall biases which is a limitation of cross-sectional research. Additionally, we did 
not examine other sleep disorders such as sleep-related movement disorders, circadian 
rhythm disorders, parasomnias or excessive daytime sleepiness; thus hidden sleep 
pathology may not have been detected. Finally, with the study being cross-sectional we are 
limited in our ability to explore the causal ordering of variable relationships. 
In summary, our findings suggest that sleep disturbance more common than previously 
thought in psoriasis and that it is associated with a range of psychological and physical 
factors. Whilst a handful of studies have shown improvements in sleep in psoriasis following 
administration of biologic medication94 95, this should be combined with psychological 
therapies specifically targeting the modifiable factors identified here including, including itch, 
negative mood and pre-sleep arousal. Therapeutic focus on these variables may lead to 
improvements in sleep in people with psoriasis. 
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Variable Score Min Max
Gender, % male/female 24.7/75.3
Age, mean (SD), y 39.2 (12.63) 18 70
BMI, mean (SD) 30.7 (9.37) 13.15 78.9
Alcohol, mean (SD), units per week 4.21 (9.35) 0 70
PSQI score, mean (SD)a 9.24 (4.32) 2 20
Normal sleepers (≤5), n (%) 44 (23.7)
Poor sleepers (≥6), n (%) 142 (76.3)
OSA probability
Low, n (%) 125 (67.2)
High, n (%) 61 (32.8)
PSAS
Cognitive Arousal, mean (SD) 21.01  (7.5) 8 40
Somatic Arousal, mean (SD) 14.53 (5.84) 8 33
MEQ, mean (SD) 51.43 (9.98) 19 75
Morning type, n (%) 43 (23.1)
Intermediate type, n (%) 117 (62.9)
Evening type, n (%) 26 (14)
Itch, mean (SD) 13.99 (4.27) 5 25
Psoriasis severity, mean (SD)b 9.56 (8.58) 0 48
Mild, n (%) 110 (59.1%)
Moderate, n (%) 57 (30.6%)
Severe, n (%) 19 (10.2%)
HADS
Depression, mean (SD) 6.52 (4.24) 0 20
Anxiety, mean (SD) 8.56 (4.34) 0 21
aScores range from 0-21, higher values indicate poorer sleep
bScores range from 0-50, higher values represent more severe psoriasis
Abbreviations: BMI: Body Mass Index, PSQI: Pittsburgh Sleep Quality Index, OSA: Obstructive 
Sleep Apnea, PSAS: Pre-sleep arousal scale, MEQ: Morningness-Eveningness 
Questionnaire, HADS: Hospital Anxiety and Depression Scale
Variables 1 2 3 4 5 6 7 8 9 10 11 12
1. Sleep quality (PSQI) .337* .435* .496* .452* .484* .462* -.239* .343* -.014 -.067 .140
2. Psoriasis (SPI-S) .227* .336* .550* .236* .061 -.075 .165* .064 .184* .174*
3. Anxiety (HADS-A) .517* .267* .557* .641* -.105 .252* -.071 -.112 .020
4. Depression (HADS-D) .380* .459* .346* -.102 .348* .036 .085 .076
5. Itch (5D Itch Scale) .357* .178* -.156* .186* .040 .021 .168*
6. Somatic Arousal (PSAS-S) .477* -.131 .299* -.033 -.124 .085
7. Cognitive Arousal (PSAS-C) -.227* .141 -.047 -.080 -.051
8. Chronotype (MEQ) -.013 .244* 0.88 -.054
9. OSA probability (Berlin Questionnaire) .139 0.24 .268*
10. Age .193* .230*
11. Sex -.070
12. BMI
*p<.05
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 Predictor b
Model
Itch .263
Cognitive Arousal .152
Depression .241
Somatic Arousal .124
Anxiety -.020
Dependent variable: Sleep quality (PSQI total)
b, unstandardised regression coefficient; SE, stand
probaility; R2, proportion of variance explained
SE β t p R2
.430
.063 .260 4.16 .000
.043 .264 3.54 .001
.071 .237 3.39 .001
.054 .168 2.31 .022
.083 -.020 -.24 .809
ard error; β, standardised regression coefficient; t, obtained t-value
 
 
; p, 
